Literature DB >> 17599056

MMP-2 siRNA induced Fas/CD95-mediated extrinsic II apoptotic pathway in the A549 lung adenocarcinoma cell line.

C Chetty1, P Bhoopathi, S S Lakka, J S Rao.   

Abstract

We have previously reported that the downregulation of MMP-2 by adenovirus-mediated delivery of MMP-2 siRNA (Ad-MMP-2) reduced spheroid invasion and angiogenesis in vitro, and, metastasis and tumor growth in vivo. In this study, we investigated the mechanism of Ad-MMP-2-mediated growth inhibition in vitro and in vivo. Ad-MMP-2 infection led to the induction of apoptosis as determined by TUNEL assay, Annexin-V staining and PARP-1 cleavage in a dose-dependent manner in A549 cells. Ad-MMP-2 decreased the content of the antiapoptotic members of the Bcl-2 family proteins (Bcl-2 and Bcl-xL) and increased the content of the pro-apoptotic members of the Bcl-2 family (Bax and Bcl-xS) as determined by immunoblotting analysis. Furthermore, Ad-MMP-2-mediated apoptosis was accompanied by increase in truncated Bid, release of cytochrome c and the activation of caspase-8, -9 and -3. Immunoblot analysis showed that Ad-MMP-2 infection caused upregulation of Fas/Fas-L and FADD, and Anti-Fas-L antibody reversed Ad-MMP-2-induced apoptosis. Tissue inhibitor of metalloproteinases (TIMP)-3, an endogenous inhibitor of MMP-2, which cleaves Fas-L and activates the Fas/Fas-L inducing apoptotic pathway, was increased in Ad-MMP-2-treated cells. Adenovirus-mediated expression of MMP-2 siRNA in human lung xenografts in vivo resulted in increased immunostaining of Fas, Fas-L, cleaved Bid and TIMP-3. This is the first report, to our knowledge, showing that MMP-2 inhibition upregulates TIMP-3 levels, which in turn, promotes apoptosis in lung cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17599056      PMCID: PMC2167629          DOI: 10.1038/sj.onc.1210584

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  31 in total

Review 1.  The biochemistry of apoptosis.

Authors:  M O Hengartner
Journal:  Nature       Date:  2000-10-12       Impact factor: 49.962

2.  Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway.

Authors:  Mark Bond; Gillian Murphy; Martin R Bennett; Andrew C Newby; Andrew H Baker
Journal:  J Biol Chem       Date:  2002-02-04       Impact factor: 5.157

3.  Localization of the death domain of tissue inhibitor of metalloproteinase-3 to the N terminus. Metalloproteinase inhibition is associated with proapoptotic activity.

Authors:  M Bond; G Murphy; M R Bennett; A Amour; V Knauper; A C Newby; A H Baker
Journal:  J Biol Chem       Date:  2000-12-29       Impact factor: 5.157

Review 4.  Tissue inhibitors of metalloproteinases: evolution, structure and function.

Authors:  K Brew; D Dinakarpandian; H Nagase
Journal:  Biochim Biophys Acta       Date:  2000-03-07

5.  Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption.

Authors:  H Haro; H C Crawford; B Fingleton; K Shinomiya; D M Spengler; L M Matrisian
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

6.  Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue.

Authors:  K Brand; A H Baker; A Perez-Cantó; A Possling; M Sacharjat; M Geheeb; W Arnold
Journal:  Cancer Res       Date:  2000-10-15       Impact factor: 12.701

7.  Transcriptional inactivation of the tissue inhibitor of metalloproteinase-3 gene by dna hypermethylation of the 5'-CpG island in human gastric cancer cell lines.

Authors:  S H Kang; H H Choi; S G Kim; H S Jong; N K Kim; S J Kim; Y J Bang
Journal:  Int J Cancer       Date:  2000-06-01       Impact factor: 7.396

8.  Adenovirus-mediated small interfering RNA against matrix metalloproteinase-2 suppresses tumor growth and lung metastasis in mice.

Authors:  Chandramu Chetty; Praveen Bhoopathi; Pushpa Joseph; Subramanyam Chittivelu; Jasti S Rao; Sajani Lakka
Journal:  Mol Cancer Ther       Date:  2006-09       Impact factor: 6.261

Review 9.  Induction of tumour cell apoptosis by matrix metalloproteinase inhibitors: new tricks from a (not so) old drug.

Authors:  N Mitsiades; V Poulaki; C S Mitsiades; K C Anderson
Journal:  Expert Opin Investig Drugs       Date:  2001-06       Impact factor: 6.206

10.  Antitumor activity and bystander effect of adenovirally delivered tissue inhibitor of metalloproteinases-3.

Authors:  Matti Ahonen; Risto Ala-Aho; Andrew H Baker; Sarah J George; Reidar Grénman; Ulpu Saarialho-Kere; Veli-Matti Kähäri
Journal:  Mol Ther       Date:  2002-06       Impact factor: 11.454

View more
  26 in total

1.  Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein.

Authors:  Ju-Hwa Kim; Minji Chae; Won Ki Kim; You-Jin Kim; Han Sung Kang; Hyung Sik Kim; Sungpil Yoon
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

2.  Targeting MMP-9, uPAR, and cathepsin B inhibits invasion, migration and activates apoptosis in prostate cancer cells.

Authors:  A K Nalla; B Gorantla; C S Gondi; S S Lakka; J S Rao
Journal:  Cancer Gene Ther       Date:  2010-05-07       Impact factor: 5.987

3.  Vicenin-2: a potential radiosensitizer of non-small cell lung cancer cells.

Authors:  Taranga Jyoti Baruah; R N Sharan; Lakhan Kma
Journal:  Mol Biol Rep       Date:  2018-08-11       Impact factor: 2.316

4.  SPARC stimulates neuronal differentiation of medulloblastoma cells via the Notch1/STAT3 pathway.

Authors:  Praveen Bhoopathi; Chandramu Chetty; Ranadheer Dontula; Meena Gujrati; Dzung H Dinh; Jasti S Rao; Sajani S Lakka
Journal:  Cancer Res       Date:  2011-05-25       Impact factor: 12.701

Review 5.  Matrix metalloproteinases in tumorigenesis: an evolving paradigm.

Authors:  Hui Hua; Minjing Li; Ting Luo; Yancun Yin; Yangfu Jiang
Journal:  Cell Mol Life Sci       Date:  2011-07-10       Impact factor: 9.261

6.  MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells.

Authors:  Chandramu Chetty; Sajani S Lakka; Praveen Bhoopathi; Jasti S Rao
Journal:  Int J Cancer       Date:  2010-09-01       Impact factor: 7.396

7.  HIV infection model of chronic obstructive pulmonary disease in mice.

Authors:  Patrick Geraghty; Eran Hadas; Boe-Hyun Kim; Abdoulaye J Dabo; David J Volsky; Robert Foronjy
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-01-19       Impact factor: 5.464

8.  MicroRNA-148a reduces tumorigenesis and increases TRAIL-induced apoptosis in NSCLC.

Authors:  Pooja Joshi; Young-Jun Jeon; Alessandro Laganà; Justin Middleton; Paola Secchiero; Michela Garofalo; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-29       Impact factor: 11.205

9.  SPARC mediates Src-induced disruption of actin cytoskeleton via inactivation of small GTPases Rho-Rac-Cdc42.

Authors:  Praveen Bhoopathi; Christopher S Gondi; Meena Gujrati; Dzung H Dinh; Sajani S Lakka
Journal:  Cell Signal       Date:  2011-07-23       Impact factor: 4.315

10.  The role of MMP-9 in the anti-angiogenic effect of secreted protein acidic and rich in cysteine.

Authors:  P Bhoopathi; C Chetty; M Gujrati; D H Dinh; J S Rao; S S Lakka
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.